Imexpharm Corporation (HOSE:IMP)
Vietnam · Delayed Price · Currency is VND 35,100
+100 (0.29%)
At close: Nov 3, 2026
Imexpharm Ratios and Metrics
Market cap in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,405,715 | 8,085,471 | 7,238,421 | 3,962,167 | 4,013,628 | 5,187,048 | |
Market Cap Growth | -29.94% | 11.70% | 82.69% | -1.28% | -22.62% | 38.19% |
Enterprise Value | 5,094,762 | 8,062,671 | 7,072,195 | 3,840,834 | 3,828,514 | 5,172,206 |
Last Close Price | 35100.00 | 51735.44 | 45871.90 | 24801.67 | 24761.53 | 31286.47 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.86 | 26.56 | 26.24 | 14.26 | 21.83 | 29.89 |
Forward PE | 15.23 | 22.97 | 20.30 | 11.68 | 19.00 | 21.00 |
PS Ratio | 2.36 | 3.31 | 3.28 | 1.99 | 2.44 | 4.10 |
PB Ratio | 2.23 | 3.51 | 3.32 | 1.90 | 2.12 | 2.89 |
P/TBV Ratio | 2.30 | 3.62 | 3.43 | 1.97 | 2.20 | 3.01 |
P/FCF Ratio | 15.42 | 296.26 | 60.57 | - | 14.37 | 28.50 |
P/OCF Ratio | 13.92 | 149.26 | 33.47 | - | 10.60 | 22.08 |
PEG Ratio | - | 1.99 | 1.99 | 1.99 | 2.71 | 0.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.22 | 3.30 | 3.21 | 1.93 | 2.33 | 4.08 |
EV/EBITDA Ratio | 9.04 | 14.26 | 13.58 | 8.28 | 10.73 | 17.56 |
EV/EBIT Ratio | 11.00 | 17.43 | 17.04 | 10.08 | 12.91 | 22.10 |
EV/FCF Ratio | 14.53 | 295.42 | 59.18 | - | 13.71 | 28.42 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.09 | 0.04 | 0.02 | 0.05 | 0.15 |
Debt / EBITDA Ratio | 0.38 | 0.38 | 0.17 | 0.11 | 0.27 | 0.90 |
Debt / FCF Ratio | 0.60 | 7.80 | 0.72 | - | 0.34 | 1.45 |
Net Debt / Equity Ratio | -0.13 | -0.08 | -0.10 | -0.07 | -0.16 | -0.07 |
Net Debt / EBITDA Ratio | -0.55 | -0.33 | -0.42 | -0.32 | -0.83 | -0.41 |
Net Debt / FCF Ratio | -0.89 | -6.91 | -1.82 | 1.45 | -1.06 | -0.66 |
Asset Turnover | 0.77 | 0.92 | 0.90 | 0.85 | 0.72 | 0.58 |
Inventory Turnover | 1.65 | 1.85 | 1.68 | 1.78 | 1.78 | 1.46 |
Quick Ratio | 2.28 | 1.96 | 2.00 | 1.49 | 1.62 | 1.56 |
Current Ratio | 4.00 | 4.05 | 4.38 | 3.92 | 2.89 | 2.88 |
Return on Equity (ROE) | 15.89% | 15.55% | 15.04% | 15.06% | 12.12% | 10.73% |
Return on Assets (ROA) | 9.77% | 10.93% | 10.60% | 10.20% | 8.11% | 6.66% |
Return on Invested Capital (ROIC) | 17.80% | 17.72% | 16.90% | 17.12% | 13.89% | 10.94% |
Return on Capital Employed (ROCE) | 18.30% | 19.20% | 19.00% | 18.30% | 15.70% | 12.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.93% | 4.32% | 4.43% | 7.56% | 5.57% | 3.65% |
FCF Yield | 6.49% | 0.34% | 1.65% | -2.60% | 6.96% | 3.51% |
Dividend Yield | 1.43% | - | 1.06% | 1.77% | 1.66% | 1.93% |
Payout Ratio | 25.15% | 22.05% | 21.82% | 22.26% | 44.74% | 52.89% |
Buyback Yield / Dilution | - | - | - | 0.00% | 0.00% | -2.92% |
Total Shareholder Return | 1.43% | - | 1.06% | 1.77% | 1.66% | -0.99% |